Supplementary Figure S2 from Prospective Phase II Study on 5-Days Azacitidine for Treatment of Symptomatic and/or Erythropoietin Unresponsive Patients with Low/INT-1–Risk Myelodysplastic Syndromes
التفاصيل البيبلوغرافية
العنوان:
Supplementary Figure S2 from Prospective Phase II Study on 5-Days Azacitidine for Treatment of Symptomatic and/or Erythropoietin Unresponsive Patients with Low/INT-1–Risk Myelodysplastic Syndromes
American Association for Cancer Research (AACR), 2023.
سنة النشر:
2023
الوصف:
Supplementary Figure S2 - PDF file 145K, Representation from Chromosome Analysis Suite (Chas, Affymetrix) of LOH alterations in analyzed MDS patients.The figure represents the LOH of the 5 patients with this abnormality and shows its distribution and its size within the chromosomes
